Cerity Partners’s INmune Bio INMB Stock Holding History

Cerity Partners’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$54.2K	Buy	33,230 +19,188	+137%	+$26.5K	﹤0.01%	3292
2026 Q1	$15.9K	Buy	+14,042	New	+$20K	﹤0.01%	3191

Other funds holding INMB

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Cerity Partners's INMB Position: Q2 2026 in Review

Cerity Partners increased its INmune Bio (INMB) stake by 137% in Q2 2026, buying an estimated $26.5K and bringing the position to 33,230 shares worth $54.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3292.

Cerity Partners first reported a position in INMB in Q1 2026 and has held it in 2 quarters since. 83 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

Cerity Partners held 33,230 shares of INmune Bio worth $54.2K as of Q2 2026.
Cerity Partners bought 19,188 INmune Bio shares in Q2 2026, an estimated $26.5K.
INmune Bio made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #3292 holding.
Cerity Partners first reported a position in INmune Bio in Q1 2026 and has held it in 2 quarters since.
83 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.